Skip to main content
Premium Trial:

Request an Annual Quote

Sanford-Burnham Taps Genedata Screener for Chemical Genomics

Premium

Genedata said this week that Sanford-Burnham's chemical genomics arm has selected its Screener software to parse libraries containing chemical compounds and natural products as part of its drug discovery pipeline.

Specifically, researchers at two sites that are part of the Conrad Prebys Center for Chemical Genomics are using the platform to process high-content and high-throughput screening data.

They will use the system to determine the best datasets for hit selection as well as identify hits that "may otherwise be lost," Christian Hassig, director of drug discovery at the center, said in a statement.

According to Susanne Heynen-Genel, who directs the HCS core facility at the center, Genedata Screener "eliminates tedious manual handling of single plates and the lag time traditionally experienced when accessing different systems and files."

For researchers involved in HTS data processing at Sanford-Burnham, Screener replaces plate-by-plate analysis, which is time-consuming and error-prone, Ying Su, director of cheminformatics and HTS Informatics at the chemical genomics center, said in a statement.

Financial details about the Sanford-Burnham licensing agreement were not disclosed.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.